US9234006B2 - Compounds - Google Patents

Compounds Download PDF

Info

Publication number
US9234006B2
US9234006B2 US14/356,868 US201214356868A US9234006B2 US 9234006 B2 US9234006 B2 US 9234006B2 US 201214356868 A US201214356868 A US 201214356868A US 9234006 B2 US9234006 B2 US 9234006B2
Authority
US
United States
Prior art keywords
polymyxin
nonapeptide
alkyl
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US14/356,868
Other languages
English (en)
Other versions
US20150031602A1 (en
Inventor
Mona Saadi
Esther Duperchy
Pamela Brown
Michael John Dawson
Sjoerd Nicolaas Wadman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CANTAB BIOPHARMACEUTICALS Ltd
Novacta Holdings PLC
Novacta Biosystems Ltd
Spero Therapeutics Inc
Original Assignee
CANTAB ANTI-INFECTIVES Ltd
Novacta Biosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US14/356,868 priority Critical patent/US9234006B2/en
Application filed by CANTAB ANTI-INFECTIVES Ltd, Novacta Biosystems Ltd filed Critical CANTAB ANTI-INFECTIVES Ltd
Assigned to NOVACTA BIOSYSTEMS LIMITED reassignment NOVACTA BIOSYSTEMS LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WADMAN, SJOERD NICOLAAS, DAWSON, MICHAEL JOHN, BROWN, PAMELA, DUPERCHY, Esther, SAADI, Mona
Assigned to CANTAB ANTI-INFECTIVES LIMITED reassignment CANTAB ANTI-INFECTIVES LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CANTAB BIOPHARMACEUTICALS LIMITED
Assigned to CANTAB BIOPHARMACEUTICALS LIMITED reassignment CANTAB BIOPHARMACEUTICALS LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DUPERCHY, Esther, BROWN, PAMELA, DAWSON, MICHAEL JOHN, SAADI, Mona
Publication of US20150031602A1 publication Critical patent/US20150031602A1/en
Publication of US9234006B2 publication Critical patent/US9234006B2/en
Application granted granted Critical
Assigned to NOVACTA BIOSYSTEMS LIMITED reassignment NOVACTA BIOSYSTEMS LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CANTAB ANTI-INFECTIVES LIMITED
Assigned to NOVACTA HOLDINGS PLC reassignment NOVACTA HOLDINGS PLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVACTA BIOSYSTEMS LIMITED
Assigned to NEW PHARMA LICENCE HOLDINGS LIMITED reassignment NEW PHARMA LICENCE HOLDINGS LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVACTA HOLDINGS PLC
Assigned to SPERO THERAPEUTICS, INC. reassignment SPERO THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NEW PHARMA LICENCE HOLDINGS LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present disclosure relates to novel compounds, pharmaceutical compositions comprising said compounds and the use of the said compounds and pharmaceutical compositions for treatment, for example treatment of microbial infections, particularly by Gram negative bacteria.
  • Gram negative bacteria can cause serious complications and infections, such as pneumonia, urinary tract infections, wound infections, ear infections, eye infections, intra-abdominal infections, oral bacterial overgrowth and sepsis.
  • the treatment of serious bacterial infections in clinical practice can be complicated by antibiotic resistance.
  • Recent years have seen a rise in infections by Gram negative bacteria which are resistant to many types of antimicrobials including broad spectrum antibiotics such as aminoglycosides, cephalosporins and even carbapenems. There is therefore a need to identify new antimicrobials that are effective against Gram negative bacteria, in particular against multidrug resistant Gram negative bacteria.
  • Polymyxins are a class of antibiotics produced by the Gram positive bacterium Bacillus polymyxa .
  • polymyxins particularly polymyxin B and polymyxin E (colistin) were used in the treatment of Gram negative infections.
  • these antibiotics exhibited side effects such as nephrotoxicity. Consequently, their use in therapy is limited to treatment of last resort.
  • WO 2008/017734 tries to address this toxicity problem by providing polymyxin derivatives carrying at least two but no more than three positive charges. These compounds are said to be effective antibacterial agents with reduced toxicity. It is hypothesised in the disclosure that the reduced number of positive charges decreases the affinity of the compound for isolated rat kidney tissue which in turn may lead to a reduction in nephrotoxicity.
  • polymyxin type compounds including some with 4 or more charges have suitable antibacterial activity whilst also apparently exhibiting less toxicity, especially nephrotoxicity.
  • the compounds of formula (I) are characterised in that the peptide part of the molecule contains only nine amino acids whereas natural polymyxins comprise 10 amino acids.
  • polymyxin type compounds results from a detergent-like interaction with membranes of eukaryotic cells.
  • nephrotoxicity of polymyxin type compounds may result from the fact that they are retained in kidney cells and thus accumulate rather than being excreted from the body.
  • the compounds of the present invention have a group R 5 which comprises a substituent which disrupts the hydrophobicity of the alkyl component thereof. The inventors believe that this disruption changes the balance of hydrophobic and hydrophilic nature of the molecules which means they are less well suited for aligning themselves in bilipid-layers which form membranes. In turn this inability to align in the membrane may result in lower residency time therein and thus may result in lower toxicity.
  • Polymyxin nonapeptide as employed herein is intended to refer to amino acids 2-10 of polymyxin B or polymyxin E.
  • amino acid residue for example a leucine residue, etc.
  • an amino acid residue as employed herein is intended to refer to an amino acid that has lost a water molecule and forms a bond with another entity (such as another amino acid) through the carbonyl end thereof and also forms a bond through the nitrogen end thereof to another entity (such as another amino acid).
  • the bonds formed may for example be amide bonds.
  • Alkyl as used herein refers to straight chain or branched chain alkyl, such as, without limitation, methyl, ethyl, n-propyl, iso-propyl, butyl, n-butyl and tert-butyl. In one embodiment alkyl refers to straight chain alkyl.
  • Alkyl in the context of a linker molecule i.e. substitute alkyl
  • Branches may terminate in alkyl radical such as —CH 3 .
  • Heterocyclyl as employed herein is a saturated carbocyclic ring comprising at least one nitrogen ring atom, for example 1 or 2 nitrogen ring atoms, such as only 1 nitrogen ring atom and optionally containing a further ring heteroatom selected from oxygen and sulfur.
  • Examples of C 4-6 heterocyclyl groups include azetidine, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl.
  • the heterocyclyl is linked to the remainder of the molecule through nitrogen.
  • C 4-6 heterocyclyl the expression C 4-6 represents the total number of ring atoms, including carbon and heteroatoms.
  • R 1 together with the carbonyl group and nitrogen alpha to the carbon to which it is attached represents a phenylalanine residue, for example a D-phenylalanine or a leucine residue, such as a D-leucine residue.
  • R 2 together with the carbonyl group and nitrogen alpha to the carbon to which it is attached represents a leucine residue.
  • R 3 together with the carbonyl group and nitrogen alpha to the carbon to which it is attached represents a threonine residue.
  • R 4 together with the carbonyl group and nitrogen alpha to the carbon to which it is attached represents ⁇ , ⁇ -diaminobutyric acid (Dab) or a serine residue, for example L-Dab or D-Ser.
  • X represents —C( ⁇ O).
  • R 5 represents azetidine, pyrrolidinyl or piperidinyl.
  • R 5 C 2-12 alkyl component is C 2 alkyl, C 3 alkyl, C 4 alkyl, C 5 alkyl, C 6 alkyl, C 7 alkyl, C 8 alkyl, C 9 alkyl, C 10 alkyl, C 11 alkyl or C 12 alkyl.
  • R 5 C 2-12 alkyl component is C 3-10 alkyl, for example C 4-8 alkyl.
  • R 5 is C 3-8 cycloalkyl, for example C 5 cycloalkyl or C 6 cycloalkyl.
  • R 5 bears one substituent.
  • R 5 bears two substituents.
  • R 5 bears three substituents.
  • R 5 bears one, two or three hydroxyl groups, for example one hydroxyl group.
  • R 5 bears one amine group, for example a C 2-12 alkyl bearing one amine, such as C 2-4 alkyl bearing one amine.
  • R 5 bears one, two or three hydroxyl groups, such as one hydroxyl.
  • R 5 bears one amine group and one hydroxyl group.
  • R 5 bears one amine group and two hydroxyl groups.
  • R 5 bears one or more hydroxyls then the alkyl chain is C 5-12 .
  • R 5 does not bear more than one amine group.
  • R 5 bears more than one substituent
  • the substituents are not located on the same carbon atom.
  • At least one R 5 substituent (such as one substituent) is located on C 2 alkyl, C 3 alkyl, C 4 alkyl, C 5 alkyl, C 6 alkyl, C 7 alkyl, C 8 alkyl, C 9 alkyl, C 10 alkyl, C 11 alkyl or C 12 alkyl.
  • At least one R 5 substituent (such as one substituent) is on a terminal carbon of a straight alkyl chain or an alkyl branch, for example a straight alkyl chain.
  • alkyl As used herein is in fact a generic term which covers the situation wherein part or all of the alkyl moiety is in fact an alkylene moiety.
  • Terminal carbon as employed herein is intended to refer to carbon that would be a —CH 3 if it bore no substituents.
  • At least one (such as only one) substituent is not on a terminal carbon, i.e. —CH(substituent)-.
  • R 6 is hydrogen
  • R 6 is C 1-4 alkyl, such as C 1 alkyl, C 2 alkyl, C 3 alkyl or C 4 alkyl, for example methyl.
  • R 7 is hydrogen
  • R 7 is C 1-4 alkyl such as C 1 alkyl, C 2 alkyl, C 3 alkyl or C 4 alkyl, for example methyl.
  • both R 6 and R 7 represent methyl.
  • R 6 represents H and R 7 represents methyl.
  • R 5 is selected from —CH(OH)(CH 2 ) 5 CH 3 , —CH 2 NH 2 , —CH 2 CH 2 NH 2 , —CH 2 CH 2 CH 2 NH 2 , —(CH 2 ) 5 NH 2 , —(CH 2 ) 7 NH 2 , —CH 2 CH 2 NHCH 3 , —CH 2 CH 2 N(CH 3 ) 2 , and —(CH 2 ) 7 OH.
  • R 8 is methyl
  • R 8 is hydrogen
  • the compound is of formula (Ia):
  • the compound of formula (Ia) is a polymyxin nonapeptide having amino acids 2-10 of polymyxin B.
  • the compound of formula (Ia) is a polymyxin nonapeptide having amino acids 2-10 of polymyxin E.
  • a compound of formula (I) has three positive charges.
  • a compound of formula (I) has four or five positive charges, such as four.
  • a compound of formula (I) has five positive charges.
  • a compound of formula (I) has six positive charges.
  • the compound is selected from:
  • salts of compound of formula (I) include all pharmaceutically acceptable salts, such as, without limitation, acid addition salts of strong mineral acids such as HCl and HBr salts and addition salts of strong organic acids such as a methanesulfonic acid salt. Further examples of salts include sulphates and acetates such as trifluoroacetate or trichloroacetate.
  • the compounds of the present disclosure are provided as a sulphate salt.
  • a compound of the disclosure can also be formulated as prodrug.
  • Prodrugs can include an antibacterial compound herein described in which one or more amino groups are protected with a group which can be cleaved in vivo, to liberate the biologically active compound.
  • the prodrug is an “amine prodrug”.
  • examples of amine prodrugs include sulphomethyl, as described in e.g., Bergen et al, Antimicrob. Agents and Chemotherapy, 2006, 50, 1953 or HSO 3 —FMOC, as described in e.g. Schechter et al, J. Med Chem 2002, 45(19) 4264, and salts thereof. Further examples of amine prodrugs are given by Krise and Oliyai in Biotechnology: Pharmaceutical Aspects, 2007, 5(2), 101-131.
  • the compounds of the invention are provided as a prodrug.
  • solvates of compounds of formula (I) include hydrates.
  • the compounds of the disclosure include those where the atom specified is replaced by a naturally occurring or non-naturally occurring isotope.
  • the isotope is a stable isotope.
  • the compounds of the disclosure include, for example deuterium containing compounds and the like.
  • the present invention provides compounds having amino acids 2-10 of polymyxin B, or a variant thereof as described below, wherein the N terminal of the amino acid corresponding to residue 2 in polymyxin B, is modified with a group R 5 —X—.
  • the variables R 5 and X are as defined above.
  • residue 1 of polymyxin B is absent.
  • a variant of the compound is a compound in which one or more, for example, from 1 to 5, such as 1, 2, 3 or 4 amino acids are substituted by another amino acid.
  • the amino acid is at a position selected from positions 2, 3, 6, 7 or 10 (referring to the numbering of residues used in polymyxin B).
  • the substitution may be for another amino acid or for a stereoisomer.
  • the variant may have a D-Ser substitution.
  • the variant may have a Ser substitution.
  • the variant may have a Leu or Val substitution.
  • a position 7, the variant may have a Ile, Phe, Thr, Val or Nva (norvaline) substitution.
  • the variant may have a Leu substitution.
  • a polymyxin E compound may be regarded as a polymyxin B compound having a Leu substitution at position 6.
  • the compounds of the invention are represented by the formula (I) where the amino acids at positions 2, 3, 6, 7 or 10 are determined by the nature of the groups R 8 , R 4 , R 1 , R 2 and R 3 respectively.
  • Compounds of the invention, which include the variants described above, are biologically active.
  • Compounds of formula (I) can be prepared by conventional peptide synthesis, using methods known to those skilled in the art. Suitable methods include solution-phase synthesis such as described by Yamada et al, J. Peptide Res. 64, 2004, 43-50, or by solid-phase synthesis such as described by de Visser et al, J. Peptide Res, 61, 2003, 298-306, and Vaara et al, Antimicrob. Agents and Chemotherapy, 52, 2008. 3229-3236. These methods include a suitable protection strategy, and methods for the cyclisation step. Alternatively, compounds may be prepared from readily available polymyxins, for example by removal of the N-terminal amino acid of the polymyxin (residue 1). Such a method is described herein for the preparation of compounds based on residues 2-10 of polymyxins B and E.
  • the invention also provides a method of preparing certain compound of formula (I) by reacting a compound of formula (II):
  • the reaction may be performed in a suitable solvent such as dichloromethane, optionally in the presence of base such as triethylamine or N-ethyldiisopropylamine (DIPEA).
  • a suitable solvent such as dichloromethane
  • base such as triethylamine or N-ethyldiisopropylamine (DIPEA).
  • R 5 is defined above, in the presence of base, as described in Gallon et al, J. Org. Chem., 2005, 70, 6960.
  • the reaction may be performed in a suitable solvent, such as a polar aprotic solvent such as dichloromethane.
  • a suitable solvent such as a polar aprotic solvent such as dichloromethane.
  • R 5 R 5 —COOH (IIIc) wherein R 5 is defined above, for example in the presence of a coupling agent such as HATU, (O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate), HBTU ((2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate), DCC (dicyclohexyl carbodiimide), or PYBOP (benzotriazole-1-yl-oxy-tri-pyrrolidono-phosphonium hexafluorophosphate), under basic conditions in a polar solvent.
  • a coupling agent such as HATU, (O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate), HBTU ((2-
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I), for example a therapeutically effective amount thereof and a pharmaceutically acceptable excipient, diluent and/or carrier (including combinations thereof).
  • the routes for administration include, but are not limited to, one or more of: oral (e.g. as a dry powder/free flowing particulate formulation, tablet, capsule, or as an ingestible solution or suspension) buccal, sublingual.
  • oral e.g. as a dry powder/free flowing particulate formulation, tablet, capsule, or as an ingestible solution or suspension
  • buccal sublingual.
  • compositions of the disclosure include those in a form especially formulated for parenteral, oral, buccal, rectal, topical, implant, ophthalmic, nasal, rectal or genito-urinary use.
  • the agents are delivered orally, hence, the agent is in a form that is suitable for oral delivery.
  • a topical, parenteral e.g. by an injectable form
  • transdermal route including mucosal (e.g. as a nasal spray or aerosol for inhalation), nasal, gastrointestinal, intraspinal, intraperitoneal, intramuscular, intravenous, intrauterine, intraocular, intradermal, intracranial, intratracheal, intravaginal, intracerebroventricular, intracerebral, subcutaneous, ophthalmic (including intravitreal or intracameral).
  • composition/formulation requirements depending on the different delivery systems or different routes of administration.
  • the pharmaceutical composition of the present disclosure may be formulated to be delivered using a mini-pump or by a mucosal route, for example, as a nasal spray or aerosol for inhalation or ingestible solution, or parenterally in which the composition is formulated in an injectable form, for delivery by, for example, an intravenous, intramuscular or subcutaneous route.
  • the formulation may be designed to be delivered by both routes.
  • compositions can be administered by inhalation, in the form of a suppository or pessary, topically in the form of a lotion, solution, cream, ointment or dusting powder, by use of a skin patch, orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents, or they can be injected parenterally, for example intravenously, intramuscularly or subcutaneously.
  • compositions may be best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or saccharides, in particular a monosaccharide, to make the solution isotonic with blood.
  • parenteral administration include one or more of: intravenously, intraarterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially, intramuscularly or subcutaneously administering the agent, and/or by using infusion techniques.
  • the formulation of compounds of the invention is provided as a liposomal formulation.
  • Liposomes can vary in size from low micrometer range to tens of micrometers, unilamellar liposomes are typically in the lower size range with various targeting ligands attached to their surface allowing for their surface-attachment and accumulation in pathological areas for treatment of disease. Liposomes are artificially prepared vesicles made of lipid bilayer
  • the formulation is adapted for delivery by infusion or slow injection.
  • the formulation is adapted for delivery by bolus injection.
  • compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.
  • the compounds of the disclosure can be administered (e.g. orally or topically) in the form of tablets, capsules, ovules, elixirs, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications.
  • the compounds of the disclosure may also be presented for human or veterinary use in a form suitable for oral or buccal administration, for example in the form of solutions, gels, syrups, mouth washes or suspensions, or a dry powder for constitution with water or other suitable vehicle before use, optionally with flavouring and colouring agents.
  • Solid compositions such as tablets, capsules, lozenges, pastilles, pills, powder, pastes, granules, bullets or premix preparations may also be used.
  • Solid and liquid compositions for oral use may be prepared according to methods well known in the art. Such compositions may also contain one or more pharmaceutically acceptable carriers and excipients which may be in solid or liquid form.
  • the tablets may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, calcium sulphate, dibasic calcium phosphate and glycine, mannitol, pregelatinised starch, corn starch, potato starch, disintegrants such as sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia.
  • excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, calcium sulphate, dibasic calcium phosphate and glycine, mannitol, pregelatinised starch, corn starch, potato starch, disintegrants such as sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidon
  • lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.
  • compositions of a similar type may also be administered in gelatin or HPMC (hydroxypropyl methylcellulose) capsules.
  • Suitable excipients in this regard include microcrystalline cellulose, lactose, calcium carbonate, calcium sulphate, dibasic calcium phosphate and, mannitol, pregelatinised starch, corn starch, potato starch or high molecular weight polyethylene glycols.
  • the agent may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water, ethanol, propylene glycol and glycerin, and combinations thereof.
  • Capsules may be filled with a powder (of medicament alone or as blend with selected filler(s)) or alternatively a liquid, each comprising one or more salts of the present disclosure and optionally a carrier. Where the capsule is filled with a powder the salts of the present disclosure and/or the carrier may be milled or micronised to provide material with an appropriate particle size.
  • the tablet or a capsule may be filled into another capsule (preferably a HPMC capsule such as Capsugel®) to provide either a tablet in capsule or capsule in capsule configuration, which when administered to a patient yields controlled dissolution in the gastrointestinal tract thereby providing a similar effect to an enteric coating.
  • a HPMC capsule such as Capsugel®
  • the disclosure provides a solid dose formulation of a salt of the present disclosure, for example where the formulation has an enteric coating.
  • the disclosure provides a solid dose formulation comprising a protective capsule as outer layer, for example as a tablet in a capsule or a capsule in a capsule.
  • the enteric coating may provide an improved stability profile over uncoated formulations.
  • the compounds of the disclosure may also be administered orally, in veterinary medicine, in the form of a liquid drench such as a solution, suspension or dispersion of the active ingredient together with a pharmaceutically acceptable carrier or excipient.
  • a liquid drench such as a solution, suspension or dispersion of the active ingredient together with a pharmaceutically acceptable carrier or excipient.
  • the compounds of the invention may also, for example, be formulated as suppositories e.g. containing conventional suppository bases for use in human or veterinary medicine or as pessaries e.g. containing conventional pessary bases.
  • the formulation is provided as a formulation for topical administration including inhalation.
  • Suitable inhalable preparations include inhalable powders, metering aerosols containing propellant gases or inhalable solutions free from propellant gases.
  • Inhalable powders according to the disclosure containing the active substance may consist solely of the abovementioned active substances or of a mixture of the abovementioned active substances with physiologically acceptable excipient.
  • These inhalable powders may include monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose), oligo- and polysaccharides (e.g. dextranes), polyalcohols (e.g. sorbitol, mannitol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these with one another.
  • monosaccharides e.g. glucose or arabinose
  • disaccharides e.g. lactose, saccharose, maltose
  • oligo- and polysaccharides e.g. dextranes
  • polyalcohols e.g. sorbitol, mannitol, xylitol
  • salts e.g. sodium chloride, calcium carbonate
  • Particles for deposition in the lung require a particle size less than 10 microns, such as 1-9 microns suitably from 0.1 to 5 ⁇ m, particularly preferably from 1 to 5 ⁇ m.
  • propellant gases which can be used to prepare the inhalable aerosols are known from the prior art.
  • Suitable propellant gases are selected from among hydrocarbons such as n-propane, n-butane or isobutane and halohydrocarbons such as chlorinated and/or fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane.
  • hydrocarbons such as n-propane, n-butane or isobutane
  • halohydrocarbons such as chlorinated and/or fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane.
  • the above-mentioned propellant gases may be used on their own or in mixtures thereof.
  • Particularly suitable propellant gases are halogenated alkane derivatives selected from among TG11, TG 12, TG 134a and TG227.
  • halogenated alkane derivatives selected from among TG11, TG 12, TG 134a and TG227.
  • TG134a 1,1,1,2-tetrafluoroethane
  • TG227 1,1,2,3,3,3-heptafluoro propane
  • the propellant-gas-containing inhalable aerosols may also contain other ingredients such as co-solvents, stabilisers, surface-active agents (surfactants), antioxidants, lubricants and means for adjusting the pH. All these ingredients are known in the art.
  • the propellant-gas-containing inhalable aerosols according to the invention may contain up to 5% by weight of active substance. Aerosols according to the disclosure may contain, for example, 0.002 to 5% by weight, 0.01 to 3% by weight, 0.015 to 2% by weight, 0.1 to 2% by weight, 0.5 to 2% by weight or 0.5 to 1% by weight of active.
  • the salts of the disclosure may also be used in combination with other therapeutic agents.
  • the disclosure thus provides, in a further aspect, a combination comprising a salt of the present disclosure together with a further therapeutic agent.
  • the combination may, for example be a combination of a salt of the compound of formula (I) and an antibiotic, such as vancomycin, fosfomycin, rifamycin, a beta-lactam (such as a cephalosporin or carbapenem), an aminoglycoside, a macrolide, a tetracyline, a lipopeptide, an oxazolidinone and/or an anti-inflammatory such as a steroid.
  • the combination may be provided as a co-formulation or simply packaged together as separate formulations, for simultaneous or sequential delivery.
  • salts of the present disclosure in combination with a further therapeutic agent.
  • the therapy comprises more than one active component, then those components may be administered by different routes.
  • the individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations by any convenient route.
  • administration either the salt of the disclosure or the second therapeutic agent may be administered first.
  • administration is simultaneous, the combination may be administered either in the same or a different pharmaceutical composition.
  • compositions comprising a combination as defined above together with a pharmaceutically acceptable carrier or excipient comprise a further aspect of the disclosure.
  • the two compounds/salts When combined in the same formulation it will be appreciated that the two compounds/salts must be stable and compatible with each other and the other components of the formulation. When formulated separately they may be provided in any convenient formulation, in such manner as are known for such compounds in the art.
  • compositions may contain from 0.01-99% of the active material.
  • the composition will generally contain from 0.01-10%, more such as 0.01-1% of the active material.
  • each compound/salt When a salt of the disclosure is used in combination with a second therapeutic agent active against the same disease state the dose of each compound/salt may be the same or differ from that employed when the compound/salt is used alone. Appropriate doses will be readily appreciated by those skilled in the art. It will also be appreciated that the amount of a salt of the disclosure required for use in treatment will vary with the nature of the condition being treated and the age and the condition of the patient and will be ultimately at the discretion of the attendant physician or veterinarian.
  • a physician will determine the actual dosage which will be most suitable for an individual subject.
  • the specific dose level and frequency of dosage for any particular individual may be varied and will depend upon a variety of factors including the activity of the specific salt employed, the metabolic stability and length of action of that salt, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the individual undergoing therapy.
  • the daily dosage level of the agent may be in single or divided doses.
  • the daily dose as employed for adult human treatment will range from 2-100 mg/Kg body weight, such as 5-60 mg/Kg body weight, which may be administered in 1 to 4 daily doses, for example, depending on the route of administration and the condition of the patient.
  • each unit will preferably contain 100 mg to 1 g of active ingredient.
  • the duration of treatment will be dictated by the rate of response rather than by arbitrary numbers of days.
  • the treatment regime is continued for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or more days.
  • the salts of the present disclosure may be employed in the treatment or prophylaxis of humans and/or animals.
  • a process of preparing a pharmaceutical composition comprises mixing a salt of the disclosure or a pharmaceutically acceptable derivative thereof, together with a pharmaceutically acceptable excipient, diluent and/or carrier.
  • the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof or a composition comprising the same for use in therapy, and in particular, in the treatment infection such as bacterial infection, such as a Gram negative bacterial infection.
  • the compounds and compositions of the disclosure are useful in the treatment of pneumonia, urinary tract infections, wound infections, ear infections, eye infections, intra-abdominal infections, bacterial overgrowth and/or sepsis.
  • the compounds are useful in the treatment of infections by bacteria which are multidrug resistant.
  • Gram negative bacteria examples include, but are not limited to, Escherichia spp., Klebsiella spp., Enterobacter spp., Salmonella spp., Shigella spp., Citrobacter spp., Morganella morganii, Yersinia pseudotuberculosis and other Enterobacteriaceae, Pseudomonas spp., Acinetobacter spp., Moraxella, Helicobacter, Stenotrophomonas, Bdellovibrio , acetic acid bacteria, Legionella and alpha-proteobacteria such as Wolbachia and numerous others.
  • Other notable groups of Gram-negative bacteria include the cyanobacteria, spirochaetes, green sulfur and green non-sulfur bacteria.
  • Medically relevant Gram-negative cocci include three organisms, which cause a sexually transmitted disease ( Neisseria gonorrhoeae ), a meningitis ( Neisseria meningitidis ), and respiratory symptoms ( Moraxella catarrhalis ).
  • Medically relevant Gram-negative bacilli include a multitude of species. Some of them primarily cause respiratory problems ( Hemophilus influenzae, Klebsiella pneumoniae, Legionella pneumophila, Pseudomonas aeruginosa ), primarily urinary problems ( Escherichia coli, Enterobacter cloacae ), and primarily gastrointestinal problems ( Helicobacter pylori, Salmonella enterica ).
  • Gram-negative bacteria associated with nosocomial infections include Acinetobacter baumannii , which causes bacteremia, secondary meningitis, and ventilator-associated pneumonia in intensive-care units of hospital establishments.
  • the compounds and compositions of the present invention are useful in the treatment of infection of one or more of the following Gram negative bacteria: E. coli, S. enterica, Klebsiella: K. pneumoniae, K. oxytoca; Enterobacter: E. cloacae, E. aerogenes, E. agglomerans, Acinetobacter: A. calcoaceticus, A. baumannii; Pseudomonas aeruginosa, Stenotrophomonas maltophila, Providencia stuartii, Proteus:, P. mirabilis, P. vulgaris.
  • compounds of formula (I) or pharmaceutically acceptable salts thereof or compositions comprising the same are useful for the treatment of Pseudomonas infections including P. aeruginosa infection, for example skin and soft tissue infections, gastrointestinal infection, urinary tract infection, pneumonia and sepsis.
  • compounds of formula (I), or pharmaceutically acceptable salts thereof, or compositions comprising the same are useful for the treatment of Acinetobacter infections including A. baumanii infection, for pneumonia, urinary tract infection and sepsis.
  • compounds of formula (I), or pharmaceutically acceptable salts thereof, or compositions comprising the same are useful for the treatment of Klebsiella infections including K. pneumoniae infection, for pneumonia, urinary tract infection, meningitis and sepsis.
  • compounds of formula (I), or pharmaceutically acceptable salts thereof, or compositions comprising the same are useful for the treatment of E. coli infection including E. coli infections, for bacteremia, cholecystitis, cholangitis, urinary tract infection, neonatal meningitis and pneumoniae
  • the compounds of formula (I) or pharmaceutically acceptable salts thereof or compositions comprising the same may be useful for long term treatment.
  • a compound of formula (I) or a composition comprising the same for the manufacture of a medicament for one or more of the indications defined above.
  • a method of treatment comprising the step of administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutical acceptable salt thereof or a composition comprising the same to a patient (human or animal) in need thereof, for example for the treatment of an infection as described herein.
  • Polymyxin B nonapeptide was purified from the residue by SPE on C18 silica, eluting with 0-10% aqueous methanol. Evaporation of the appropriate fractions gave the product as a white solid. m/z 482, [M+2H] 2+
  • Colistin (polymyxin E, 5 g) was treated with immobilised papain (185 ELU/g), potassium phosphate buffer (25 mM; pH 7, 1.25 L), potassium chloride (30 mM), EDTA (10 mM) and cysteine (1 mM) at 37° C. for 32 h with gentle agitation to produce colistin (polymyxin E) nonapeptide.
  • the progress of the reaction was monitored by LC-MS using the conditions outlined in Intermediate 1, Table 1.
  • the immobilized papain was removed by filtration and the filtrate was concentrated in vacuo to leave a solid residue which was re-suspended in 10% aqueous methanol and left at room temperature overnight.
  • Colistin Polymyxin E nonapeptide was purified from the residue by SPE on C18 silica (10 gm), eluting with 0-25% aqueous methanol. Evaporation of the appropriate fractions gave the product as a white solid. m/z 465.32 [M+2H] 2+ .
  • Colistin Polymyxin E
  • Nonapeptide 2.5 g, 2.69 mmol
  • water 35 mL
  • Dioxane 35 mL
  • triethylamine 35 ml
  • the progress of the reaction was followed by LC-MS and reached completion after 10 minutes, whereupon the mixture was quenched by addition of 20% methanolic ammonia (25 mL).
  • the liquid phase was decanted and the residual solid was re-dissolved in water and extracted sequentially with dichloromethane and iso-butanol. Based on LC-MS analysis, the decanted liquid and both dichloromethane and iso-butanol extracts were pooled together followed by concentration in vacuo to give yellow gum which was loaded onto flash chromatography (Si 60A- 35-70). The column was eluted with 0-20% methanol (containing 2% ammonia) in dichloromethane.
  • Example 2 To the compound of Example 1 (1.3 g) was added water (1 mL) and the mixture was sonicated for 5 min. To the resulting suspension was added 1M NaHCO 3 (20 mL) until the mixture reached pH 9. The mixture was then passed through a 10 g C18 SPE column, eluting sequentially with 0, 40, 50, 60, 70, 80 and 100% aqueous methanol. LC-MS analysis of each fraction showed that the desired product eluted in the 60, 70 and 80% aqueous methanol fractions. These fractions were pooled and evaporated to leave a white solid (0.5 g), to which was added 0.1 M H 2 SO 4 (30 mL) until pH 7 was reached.
  • 2-Aminoethanoyl polymyxin B nonapeptide, sulphate salt was prepared from tetra-(Boc) polymyxin B nonapeptide and 2-(tert-butoxycarbonylamino)-ethanoic acid following the sequence of reactions described for Examples 1 and 2.
  • 3-Aminopropanoyl polymyxin B nonapeptide, sulphate salt was prepared from tetra-(Boc) polymyxin B nonapeptide and 3-(tert-butoxycarbonylamino)-propanoic acid following the sequence of reactions described for Examples 1 and 2.
  • 4-Aminobutanoyl polymyxin B nonapeptide, sulphate salt was prepared from tetra-(Boc) polymyxin B nonapeptide and 4-(tert-butoxycarbonylamino)-butanoic acid following the sequence of reactions described for Examples 1 and 2. Retention time (HPLC) 4.97 min; m/z 524.91 [M+2H] 2+ .
  • 6-Aminohexanoyl polymyxin B nonapeptide, sulphate salt was prepared from tetra-(Boc) polymyxin B nonapeptide and 6-(tert-butoxycarbonylamino)-hexanoic acid following the sequence of reactions described for Examples 1 and 2.
  • 8-Hydroxyoctanoyl polymyxin B nonapeptide, sulphate salt was prepared from tetra-(Boc) polymyxin B nonapeptide and 8-hydroxyoctanoic acid following the sequence of reactions described for Examples 1 and 2.
  • 8-Aminooctanoyl polymyxin B nonapeptide, sulphate salt was prepared from tetra-(Boc) polymyxin B nonapeptide and 8-(tert-butoxycarbonylamino)-octanoic acid following the sequence of reactions described for Examples 1 and 2.
  • Examples 15-35 were prepared using the methods of preparation set out for Examples 1 and 2 above.
  • a compound having a substituent at the polymyxin B nonapeptide N terminal was prepared from tetra-(Boc) polymyxin B nonapeptide (intermediate 2) and an appropriate carboxylic acid in the presence of coupling agents (e.g. HATU) and base (e.g. DIPEA) (as set out in Example 1a), followed by treatment with acid (e.g. TFA) (as set out in Example 1a), and an appropriate work up (as set out in Example 2).
  • coupling agents e.g. HATU
  • base e.g. DIPEA
  • acid e.g. TFA
  • a compound having a substituent at the polymyxin E nonapeptide N terminal was prepared from tetra-(Boc) colistin (polymyxin E) nonapeptide (Intermediate 4) and an appropriate carboxylic acid in the presence of coupling agents (e.g. HATU) and base (e.g. DIPEA) (as set out in Example 1b), followed by treatment with acid (e.g. TFA) (as set out in Example 1b), and conversion to the sulphate salt (as set out in Example 2).
  • coupling agents e.g. HATU
  • base e.g. DIPEA
  • acid e.g. TFA
  • MIC testing was performed by two-fold serial antibiotic dilutions in CaMHB in sterile 96-well microtitre plates in a total volume of 170 ⁇ L (150 ⁇ L broth containing the antimicrobial agent, 20 ⁇ L inoculum). The assays were performed in duplicate. Plates were incubated aerobically without shaking for 18-20 hours at 37° C. with the MIC defined as the lowest concentration of drug that prevented visible growth.
  • Table 4 shows the MIC (micrograms/mL) of Examples 2 to 14 compared to Polymyxin B (PMB),
  • Table 4A shows the MIC values obtained for compounds of Additional Examples 15 to 35 plus Examples 2, 6 and 14. Data was obtained under similar conditions to Table 4 except that different batches of cation-adjusted Muller-Hinton broth were used. The MIC values for these compounds are compared with those values obtained for Polymyxin B, Colistin Sulphate, CB-182,804 and NAB739 (as the TFA salt).
  • CB-182,804 is a polymyxin decapeptide derivative with an aryl urea substituent at the N-terminus, which has been claimed to have lower toxicity than Polymyxin B (compound 5 in WO 2010/075416. See page 37).
  • NAB739 has been described previously by Vaara et al.
  • aeruginosa ATCC27853 0.5 0.5 0.5 0.125 0.25 0.25 0.5 0.5 0.5 0.06 0.125 0.5 0.25 0.5 P. aeruginosa ATCC 9721 0.5 2 0.125 0.25 0.25 0.125 ND ND 0.5 0.125 0.25 ND 0.125 0.25 P. aeruginosa ATCC10145 0.5 1 0.25 0.5 0.5 0.25 ND 2 2 0.125 0.25 ND 0.5 0.25 P. aeruginosa ATCCCRM-9027 0.25 0.25 0.125 0.25 0.5 0.125 0.25 0.25 0.5 0.125 0.125 ND 2 0.25 K.
  • baumannii ATCCBAA-747 0.25 2 >32 1 16 ND 8 ND >32 4 1 ND 4 0.5 A. baumannii NCTC13423 0.25 1 16 1 16 ND 0.5 ND >32 2 0.5 ND 2 0.06 A. baumannii NCTC7844 0.25 2 16 4 16 2 16 >32 4 4 ND 4 0.5 ND: not determined
  • aeruginosa ATCC27853 0.5 0.5 1 1 0.5 0.25 0.25 0.25 0.25 2 0.125 0.25 1 P. aeruginosa ATCC10145 1 0.5 ND ND 1 0.5 0.5 1 ND ND 0.25 ND ND P. aeruginosa ATCC9721 0.125 0.5 ND ND 0.5 0.125 0.25 0.125 ND ND ND ND ND P. aeruginosa AATCCRM 9027 0.25 0.5 ND ND 0.5 0.25 0.125 0.125 ND ND 2 ND ND K. pneumoniae ATCC4352 0.25 0.125 ND 2 1 1 0.5 0.5 8 8 0.5 2 >32 K.
  • aeruginosa AATCCRM 9027 ND ND ND ND ND ND ND ND ND 0.5 ND ND ND ND 0.5 ND K. pneumoniae ATCC4352 32 8 0.5 0.125 4 8 0.125 0.25 0.5 1 0.5 4 4 1 1 K. pneumoniae NCTC7427 ND ND ND ND ND ND ND 0.5 ND ND ND ND 0.5 ND K. pneumoniae NCTC8172 ND ND ND ND ND ND ND ND ND ND ND >32 ND ND ND ND >32 ND K. pneumoniae ATCCBAA-1706 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND A.
  • baumannii ATCC19606 >32 >32 8 2 16 16 0.5 4 2 8 8 16 >32 1 2 A. baumannii ATCCBAA-747 ND ND ND ND ND ND ND ND 1 ND ND ND ND 1 ND A. baumannii NCTC13423 ND ND ND ND ND ND ND ND ND 0.5 ND ND ND ND 0.25 ND A. baumannii NCTC7844 ND ND ND ND ND ND ND 2 ND ND ND 2 ND ND ND: not determined
  • the in vitro antibacterial activities of the compounds of examples 2 and 6 were evaluated against a panel of 500 Gram-negative bacterial isolates alongside Colistin.
  • the panel consisted of 100 clinical isolates of each of A. baumannii, E. coli, K. pneumoniae and P. aeruginosa .
  • the panel represented the current epidemiology in Europe and the USA and included a number of relevant strains with defined resistant phenotypes to current clinically-used antibacterial agents. These resistant strains included 20 A. baumannii, 22 E. coli, 25 K. pneumoniae and 20 P. aeruginosa strains.
  • mice Groups of 5 female specific-pathogen-free CD-1 mice weighing 22 ⁇ 2 g were used. The animals were made neutropenic by intraperitoneal administration of cyclophosphamide on days ⁇ 4 (150 mg/kg) and ⁇ 1 (100 mg/kg). On Day 0, animals were inoculated intramuscularly with 10 5 CFU/mouse of Escherichia coli isolate ATCC25922 into the right thigh. At 1 h, the CFU count was determined from 5 mice and the remaining mice (five per group) were treated with a subcutaneous injection of the drug at +1 and 6 hr post-infection. In each study, there were two dose groups per test compound, 1.5 and 5 mg/kg BID, respectively.
  • Examples 2, 4, 5, 6, 7, 8, 10, 11 and polymyxin B were prepared in Normal Saline at 2 mg/mL and the solution was adjusted to pH 6-7 by addition of 0.1M H 2 SO 4 or 4.2% NaHCO 3 as required. Twenty-four hours after infection, the mice were euthanized humanely. The muscle of the right thigh of each animal was harvested, homogenized, serially diluted and plated on Brain Heart Infusion agar+0.5% charcoal (w/v) for CFU determination. Decrease of the total CFU of right thigh as compared to control counts at 24 hrs post-infection was determined for each dose group. The compounds 2 and 6 at 10 mg/kg/day demonstrated an efficacy comparable to that of polymyxin B with over 3 log 10 reduction in bacterial counts.
  • Example 14 The in vivo efficacy of the compound of Example 14 was evaluated in a mouse thigh infection model of E. coli . using the methods described in the examples above. The result is summarized in Table 5A in comparison with Polymyxin B.
  • Example 2 the in vivo efficacy of three compounds of the invention (Examples 2,6, and 14) was evaluated in a mouse thigh infection model of Klebsiella pneumoniae ATCC10031, using Colistin (Polymyxin E) as comparator.
  • Colistin Polymyxin E
  • Table 5B The results are summarized in Table 5B.
  • Drug solutions were prepared at 4 mg/mL in Normal Saline and the pH adjusted to 6-7 by adding the appropriate volume of 0.1 M H 2 SO 4 or 4.2% NaHCO 3 .
  • the solutions were filter-sterilized and stored at ⁇ 80° C. before use. On the day of the experiment, drug solutions were diluted to 1 mg/mL with sterile Normal Saline.
  • Rats were anesthetized using isofluorane and a cannula was inserted into the jugular vein.
  • rats were dosed with an intravenous bolus injection of the solution at 1 mg/kg through the cannula, followed by washing with Normal Saline.
  • Blood was collected manually through the cannula prior to administration of the compound and at 0.08, 0.25, 0.5, 1, 3, 6, 8 and 24 h thereafter.
  • Plasma was harvested by centrifugation immediately after blood collection. Twenty-four hour urine samples were collected prior to and after administration of the compound in 0-4 h, 4-6 h, and 6-24 h intervals. Plasma and urine samples were frozen at ⁇ 20° C.
  • LC-MS/MS Liquid Chromatography Mass Spectrometry
  • the pharmacokinetic parameters were determined by non-compartmental analysis using WinNonLin v5.3.
  • the urinary recovery was recorded as the percentage of intact drug recovered in the urine for the first 24 h after injection.
  • the renal cell toxicity of the compounds was assessed in an in vitro assay using the HK-2 cell line, an immortalized proximal tubule cell line derived from a normal human kidney.
  • the endpoint to describe the toxicity of the compounds was the reduction of resazurin correlating with the metabolic activity of the cells.
  • Cells were cultured in 150 cm 2 flasks in 25 mL supplemented KSF (with 5 ng/mL EGF and 50 ⁇ g/mL BPE). Cells were maintained at 70% confluence with a maximum of 25 passages.
  • Day 1 Media was removed and cells were washed with 10 ml DPBS. Six ml of a 0.25% trypsin solution with EDTA was then added to the flask and the cells returned to the incubator. After 1 to 2 minutes incubation, 14 ml media was added to the flask to inactivate the trypsin. The cell suspension was transferred to a centrifuge tube and the cells pelleted at 1000 rpm for 6 minutes.
  • the cell pellet was then resuspended in fresh media supplemented with EGF and BPE.
  • the cell number was counted and cells were diluted to 46875 cells/mL in fresh medium supplemented with EGF and BPE. 7500 cells were dispensed in each well in a volume of 160 ⁇ l and incubated at 37° C. for 24 h.
  • Test compounds were prepared directly into the media.
  • Nine point concentrations were prepared from 1000 ⁇ g/mL to 1.95 ⁇ g/mL in two-fold dilutions in fresh medium.
  • the microtiter plates were removed from the incubator and the media replaced with 100 ⁇ l of the dilutions of the compound solution. Every set of concentration was done in triplicate, and positive and negative controls were added to each plate. The plates were then incubated for 24 h at 37° C. with 5% CO 2 in a humidified atmosphere.
  • the renal cell toxicity of the additional example compounds was assessed in an in vitro assay using the HK-2 cell as described in the example above.
  • the IC 50 values for these compounds are set out in Table 7A below.
  • the renal cell toxicity Colistin, and CB182,804 (compound 5 in WO2010/075416) and NAB739 were also assessed.
  • Dose regimen used in the in vivo nephrotoxicity study are indicated in mg drug base/kg. Day 4 to Day 7 or Day 1 Day 2 Day 3 Day 10 Dose regimens a.m. p.m. a.m. p.m. a.m. p.m. a.m. p.m. 2 mg/kg bid 0.25 0.5 0.625 0.625 0.875 1.375 2 2 8 mg/kg bid 1 2 2.5 2.5 3.5 5.5 8 8
  • NAG N-acetyl-beta-D-glucosaminidase
  • Examples 2, 6, and 14 dosed using the 8 mg/kg regimen showed significantly reduced levels of the renal biomarkers NAG, albumin and cystatin C compared to Colistin at the same dose regimen (see FIGS. 1 to 3 ).
  • the response was similar to that elicited by Colistin at a maximum concentration of 2 mg/kg.
  • FIG. 1 shows the concentration of NAG (ng/24 h) at days 0, 4 and 7 for compounds 2, 6, and 14 and Colistin.
  • the left-hand graph shows from left to right Colistin (2 mg/kg BID), Colistin (8 mg/kg BID), compound 2 (8 mg/kg BID) and 6 (8 mg/kg BID).
  • the right-hand graph shows Colistin (2 mg/kg BID), Colistin (8 mg/kg BID) and compound 14 (8 mg/kg BID).
  • FIG. 2 shows the concentration of albumin (ng/24 h) at days 0, 4 and 7 for compounds 2, 6, and 14 and Colistin.
  • the left-hand graph shows from left to right Colistin (2 mg/kg BID), Colistin (8 mg/kg BID), compound 2 (8 mg/kg BID) and 6 (8 mg/kg BID).
  • the right-hand graph shows Colistin (2 mg/kg BID), Colistin (8 mg/kg BID) and compound 14 (8 mg/kg BID).
  • FIG. 3 shows the concentration of cystatin C (ng/24 h) at days 0, 4 and 7 for compounds 2, 6, and 14 and Colistin.
  • the left-hand graph shows from left to right Colistin (2 mg/kg BID), Colistin (8 mg/kg BID), compound 2 (8 mg/kg BID) and 6 (8 mg/kg BID).
  • the right-hand graph shows Colistin (2 mg/kg BID), Colistin (8 mg/kg BID) and compound 14 (8 mg/kg BID).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
US14/356,868 2011-11-18 2012-11-16 Compounds Active US9234006B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/356,868 US9234006B2 (en) 2011-11-18 2012-11-16 Compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161561361P 2011-11-18 2011-11-18
US14/356,868 US9234006B2 (en) 2011-11-18 2012-11-16 Compounds
PCT/GB2012/052844 WO2013072695A1 (en) 2011-11-18 2012-11-16 Polymyxin derivatives

Publications (2)

Publication Number Publication Date
US20150031602A1 US20150031602A1 (en) 2015-01-29
US9234006B2 true US9234006B2 (en) 2016-01-12

Family

ID=47297320

Family Applications (1)

Application Number Title Priority Date Filing Date
US14/356,868 Active US9234006B2 (en) 2011-11-18 2012-11-16 Compounds

Country Status (15)

Country Link
US (1) US9234006B2 (ru)
EP (1) EP2780357A1 (ru)
JP (1) JP6185920B2 (ru)
KR (1) KR20140091724A (ru)
CN (1) CN103946233A (ru)
AU (1) AU2012338571B2 (ru)
BR (1) BR112014012016A2 (ru)
CA (1) CA2855916A1 (ru)
CO (1) CO7061068A2 (ru)
EA (1) EA024792B1 (ru)
IL (1) IL232278A0 (ru)
MX (1) MX355217B (ru)
SG (1) SG11201402390PA (ru)
TW (1) TWI608019B (ru)
WO (1) WO2013072695A1 (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11279733B2 (en) * 2017-11-02 2022-03-22 The University Of Queensland Peptide antibiotics
US11459357B2 (en) 2018-06-25 2022-10-04 Spero Therapeutics, Inc. Polymyxin compounds

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2780357A1 (en) 2011-11-18 2014-09-24 Novacta Biosystems Limited Polymyxin derivatives
WO2014188178A1 (en) * 2013-05-22 2014-11-27 Cantab Anti-Infectives Limited Polymyxin derivatives and their use in combination therapy together with different antibiotics
KR20230152779A (ko) * 2014-03-11 2023-11-03 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도
NZ724798A (en) 2014-04-01 2020-05-29 Univ Monash Polymyxin derivatives as antimicrobial compounds
AU2015352440B2 (en) * 2014-11-26 2020-02-06 Spero Therapeutics, Inc. Compounds
CN107257803B (zh) * 2014-12-16 2021-02-05 上海盟科药业股份有限公司 用于治疗细菌感染的多粘菌素类抗菌剂
FI126143B (en) 2015-01-15 2016-07-15 Northern Antibiotics Oy Polymyxine derivative and its uses
US9763996B2 (en) 2015-01-16 2017-09-19 Northern Antibiotics, Ltd. Polymyxin derivative and uses thereof
US10322187B2 (en) 2015-08-10 2019-06-18 Lehigh University Reduced toxicity molecular conjugates of anti-fungal agents
CN108350034B (zh) * 2015-09-29 2022-03-11 莫纳什大学 抗微生物的多黏菌素衍生的化合物
JP7185622B2 (ja) * 2016-09-13 2022-12-07 センタウリ セラピューティクス リミテッド 新規化合物及びその治療上の使用
CN108226315B (zh) * 2016-12-15 2022-04-12 上海医药工业研究院 一种检测多黏菌素e残留量的分析方法
CN111690040A (zh) * 2019-03-12 2020-09-22 上海来益生物药物研究开发中心有限责任公司 多粘菌素衍生物、其制备方法和应用
JP7045520B2 (ja) * 2020-01-02 2022-03-31 上海上薬第一生化薬業有限公司 ポリミキシンｂ成分又はその塩、その製造方法及び使用
US20230141981A1 (en) 2020-01-21 2023-05-11 Shanghai Micurx Pharmaceuticals Co., Ltd Novel compounds and composition for targeted therapy of kidney-associated cancers
TW202233649A (zh) 2020-11-06 2022-09-01 美商斯佩羅治療學股份有限公司 化合物
CN112755174B (zh) * 2021-02-26 2022-11-18 沈阳药科大学 多粘菌素衍生物及其制备方法和应用
WO2022262823A1 (zh) * 2021-06-18 2022-12-22 华南理工大学 活性氧自由基响应的多粘菌素前药化合物及其应用
NL2030897B1 (en) * 2022-02-11 2023-08-18 Univ Leiden Antibiotic compounds, formulations and methods of use

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
WO1988000950A2 (en) 1986-08-06 1988-02-11 Fauchere Jean Luc Production of covalent-linked conjugates from an antibiotic and a non-toxic derivative of polymyxine b
EP0571921A2 (de) 1992-05-26 1993-12-01 Hoechst Aktiengesellschaft Cyclopeptide und deren Verwendung als Resorptionsförderer bei Applikation auf Schleimhäute
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
US20010021697A1 (en) 1987-09-14 2001-09-13 Henning Lowenstein Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
WO2008017734A1 (en) 2006-08-11 2008-02-14 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
US20080207874A1 (en) 2004-07-01 2008-08-28 Biosource Pharm, Inc. Peptide Antibiotics and Methods For Making Same
US20080279820A1 (en) 2003-09-30 2008-11-13 Hicks Terry Lee Compositions and Methods for Treating Burns
WO2009098357A1 (en) 2008-02-08 2009-08-13 Northern Antibiotics Oy Short fatty acid tail polymyxin derivatives and uses thereof
US20090215677A1 (en) 2008-02-08 2009-08-27 Martti Sakari Vaara Polymyxin derivatives and uses thereof
US20090239792A1 (en) 2008-02-08 2009-09-24 Martti Sakari Vaara Short fatty acid tail polymyxin derivatives and uses thereof
WO2010029196A1 (es) 2008-09-10 2010-03-18 Universidad De Barcelona Compuestos peptídicos antibacterianos
US20100160215A1 (en) 2008-12-23 2010-06-24 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
CN101851270A (zh) 2009-04-03 2010-10-06 梁浩 一种多粘菌素衍生物及其制备方法
WO2010130007A1 (en) 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
WO2012051663A1 (en) 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
WO2012168820A1 (en) 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2013072695A1 (en) 2011-11-18 2013-05-23 Novacta Biosystems Limited Polymyxin derivatives
WO2014188178A1 (en) 2013-05-22 2014-11-27 Cantab Anti-Infectives Limited Polymyxin derivatives and their use in combination therapy together with different antibiotics

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230152779A (ko) * 2014-03-11 2023-11-03 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
WO1988000950A2 (en) 1986-08-06 1988-02-11 Fauchere Jean Luc Production of covalent-linked conjugates from an antibiotic and a non-toxic derivative of polymyxine b
US20010021697A1 (en) 1987-09-14 2001-09-13 Henning Lowenstein Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
EP0571921A2 (de) 1992-05-26 1993-12-01 Hoechst Aktiengesellschaft Cyclopeptide und deren Verwendung als Resorptionsförderer bei Applikation auf Schleimhäute
US5565423A (en) 1992-05-26 1996-10-15 Hoechst Aktiengesellschaft Cyclopeptides and their use as absorption promoters when applied to the mucosa
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
US20080279820A1 (en) 2003-09-30 2008-11-13 Hicks Terry Lee Compositions and Methods for Treating Burns
US20080207874A1 (en) 2004-07-01 2008-08-28 Biosource Pharm, Inc. Peptide Antibiotics and Methods For Making Same
WO2008017734A1 (en) 2006-08-11 2008-02-14 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
US20090215677A1 (en) 2008-02-08 2009-08-27 Martti Sakari Vaara Polymyxin derivatives and uses thereof
WO2009098357A1 (en) 2008-02-08 2009-08-13 Northern Antibiotics Oy Short fatty acid tail polymyxin derivatives and uses thereof
US20090239792A1 (en) 2008-02-08 2009-09-24 Martti Sakari Vaara Short fatty acid tail polymyxin derivatives and uses thereof
WO2010029196A1 (es) 2008-09-10 2010-03-18 Universidad De Barcelona Compuestos peptídicos antibacterianos
US8343912B2 (en) 2008-12-23 2013-01-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2010075416A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
US20100160215A1 (en) 2008-12-23 2010-06-24 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
CN101851270A (zh) 2009-04-03 2010-10-06 梁浩 一种多粘菌素衍生物及其制备方法
WO2010130007A1 (en) 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012051663A1 (en) 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
WO2012168820A1 (en) 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
WO2013072695A1 (en) 2011-11-18 2013-05-23 Novacta Biosystems Limited Polymyxin derivatives
WO2014188178A1 (en) 2013-05-22 2014-11-27 Cantab Anti-Infectives Limited Polymyxin derivatives and their use in combination therapy together with different antibiotics

Non-Patent Citations (36)

* Cited by examiner, † Cited by third party
Title
Bergen et al., "Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa," Antimicrob. Agents and Chemotherapy, 50:1953-1958 (2006).
Bergen et al., "Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?" Diagnostic Microbiology and Infectious Disease, 74: 213-223 (2012).
CAS (Chemical Abstracts Service) Search Results, cited in a search report issued in a related United Kingdom patent application, dated Nov. 20, 2013.
de Visser et al., "Solid-phase synthesis of polymyxin B1 and analogues via a safety-catch approach," J. Peptide Res., 61:298-306 (2003).
Diaz et al., "Fast and efficient access to a family of multifunctional 1,3,5-trisubstituted piperidines," Synthetic Communications, 38:2799-2813 (2008).
Gallou et al., "Practical synthesis of unsymmetrical ureas from isopropenyl carbamates," J. Org. Chem., 70:6960-6963 (2005).
International Search Report and Written Opinion for PCT/GB2012/052844, dated Feb. 11, 2013.
International Search Report and Written Opinion issued in International Patent Application No. PCT/GB2014/051547 dated Dec. 8, 2014.
Kanazawa et al., "Contribution of Each Amino Acid Residue in Polymyxin B3 to Antimicrobial and Lipopolysaccharide Binding Activity," Chemical & Pharmaceutical Bulletin, 57: 240-244 (2009).
Katsuma et al., "Antimicrobial activity of des-fatty acyl-polymyxin B decapeptide N-terminal analogs," Peptide Science, 41:549-550 (2005).
Katsuma et al., "Development of des-fatty acyl-polymyxin B decapeptide analogs with Pseudomonas aeruginosa-specific antimicrobial activity," Chem. Pharm. Bull., 57:332-336 (2009).
Kimura et al., "Polymyxin B octapeptide and polymyxin B heptapeptide are potent outer membrane permeability-increasing agents," J. Antibiot.(Tokyo), 45:742-749 (1992).
Li et al., "Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration," Antimicrob. Agents and Chemotherapy, 47:1766-1770 (2003).
Magee et al., "Discovery of Dap-3 polymyxin analogs for the treatment of multidrug-resistant gram-negative nosocomial infections," J. Med. Chem., 56:5079-5093 (2013).
O'Dowd et al., "Preparation of tetra-Boc-protected polymyxin B nonapeptide," Tetrahedron Letters, 48:2003-2005 (2007).
Okimura et al., "Antimicrobial activity of various aminocyclohexylcarbonyl-polymyxin B (2-10) derivatives," Peptide Science, 45:243-244 (2009).
Okimura et al., "Chemical conversion of natural polymyxin B and colistin to their N-terminal derivatives," Bull. Chem. Soc. Japan, 80:543-552 (2007).
Petrosillo et al., "Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies," Clin. Microbial. Infect., 14:816-827 (2008).
Quale et al., "Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary gram-negative pathogens in New York City," Microbial Drug Resistance, 18:132-136 (2012).
Sato et al., "Des-fatty acyl-polymyxin B decapeptide analogs with antimicrobial activity specifically against Pseudemonas aeruginosa," Peptide Science, 44: 307-308 (2008).
Sato et al., "Novel des-fatty acyl-polymyxin B derivatives with Pseudomonas aeruginosa-specific antimicrobial activity," Chem. Phaim. Bull., 59:597-602 (2011).
Search Report issued in corresponding United Kingdom Patent Application No. GB1309248.1, dated Nov. 11, 2013.
Search Report issued in Great British Patent Application No. 1404301.2 dated Dec. 8, 2014.
Shechter et al., "N-[(2-Sulfo)-9-fluorenylmethoxycarbonyl]3-gentamicin C1 Is a long-acting prodrug derivative," J. Med. Chem., 45:4264-4270 (2002).
Sigma-Aldrich, "Chem Files: Peptide Synthesis," 4(2): 1-19 (2007).
Tsubery et al. N-terminal modifications of Polymyxin B nonapeptide and their effect on antibacterial activity. Peptides 2001. vol. 22, pp. 1675-1681. *
Tsubery et al., "Modulation of the Hydrophobic Domain of Polymyxin B Nonapeptide: Effect on Outer-Membrane Permeabilization and Lipopolysaccharide Neutralization," Molecular Pharmacology, 62: 1036-1042 (2002).
Vaara et al., "A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane," Antimicrob. Agents and Chemotherapy, 54:3341-3346 (2010).
Vaara et al., "Agents that increase the permeability of the outer membrane," Microbiological Reviews, 56:395-411 (1992).
Vaara et al., "Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents," Antimicrob. Agents and Chemotherapy, 52:3229-3236 (2008).
Vaara et al., "Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia coli to the direct antibacterial activity of NAB739 and to the synergistic activity of NAB7061 with rifampicin and clarithromycin," J. Antimicrob. Chemother, 65:942-945 (2010).
Velkov et al., "Teaching 'Old' Polymyxins New Tricks: New-Generation Lipopeptides Targeting Gram-Negative 'Superbugs'," ACS Chemical Biology, 9: 1172-1177 (2014).
Voitenko et al., "Relationship between structure and histamine releasing action of polymyxin B and its analogues," Agents and Actions 30:153-156 (1990).
Weinstein et al., "Selective chemical modifications of Polymyxin B," Bioorganic and Medicinal Chemistry Letters, 8: 3391-3396 (1998).
Yamada et al., "Facile synthesis of N-alpha-protected-L-alpha,gamma-diaminobutyric acids mediated by polymer-supported hypervalent iodine reagent in water," J. Peptide Res., 64:43-50 (2004).
Yousef et al., "Melatonin attenuates colistin-induced nephrotoxicity in rats," Antimicrob. Agents Chemother., 55:4044-4049 (2011).

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11279733B2 (en) * 2017-11-02 2022-03-22 The University Of Queensland Peptide antibiotics
US11459357B2 (en) 2018-06-25 2022-10-04 Spero Therapeutics, Inc. Polymyxin compounds

Also Published As

Publication number Publication date
SG11201402390PA (en) 2014-06-27
US20150031602A1 (en) 2015-01-29
KR20140091724A (ko) 2014-07-22
JP2014533678A (ja) 2014-12-15
JP6185920B2 (ja) 2017-08-23
EP2780357A1 (en) 2014-09-24
AU2012338571B2 (en) 2016-06-16
CN103946233A (zh) 2014-07-23
MX355217B (es) 2018-04-10
TWI608019B (zh) 2017-12-11
CA2855916A1 (en) 2013-05-23
IL232278A0 (en) 2014-06-30
MX2014005542A (es) 2014-10-24
EA024792B1 (ru) 2016-10-31
CO7061068A2 (es) 2014-09-19
WO2013072695A1 (en) 2013-05-23
EA201490634A1 (ru) 2014-12-30
AU2012338571A1 (en) 2014-05-22
BR112014012016A2 (pt) 2017-05-16
TW201326215A (zh) 2013-07-01

Similar Documents

Publication Publication Date Title
US9234006B2 (en) Compounds
US8937040B2 (en) Antibiotic compositions for the treatment of gram negative infections
RU2730012C2 (ru) Производные полимиксина и их применение в комбинированной терапии совместно с различными антибиотиками
US8415307B1 (en) Antibiotic compositions for the treatment of gram negative infections
TWI757229B (zh) 用於治療微生物感染的化合物以及該化合物的用途
JP2011256189A (ja) ペプチド抗生物質およびその製造方法
US20120316105A1 (en) Polymyxin Derivates Useful As Antibacterial Agents
US20170218024A1 (en) Low substituted polymyxins and compositions thereof
WO2018195078A1 (en) Anti-microbial agent-polymer conjugates and methods of use thereof
WO2016166103A1 (en) Polymyxin derivatives
CA2396513A1 (en) Pseudomycin phosphate prodrugs
TW202019949A (zh) 化合物

Legal Events

Date Code Title Description
AS Assignment

Owner name: CANTAB BIOPHARMACEUTICALS LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SAADI, MONA;DUPERCHY, ESTHER;BROWN, PAMELA;AND OTHERS;SIGNING DATES FROM 20121211 TO 20121217;REEL/FRAME:032944/0815

Owner name: CANTAB ANTI-INFECTIVES LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CANTAB BIOPHARMACEUTICALS LIMITED;REEL/FRAME:032944/0826

Effective date: 20121113

Owner name: NOVACTA BIOSYSTEMS LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WADMAN, SJOERD NICOLAAS;SAADI, MONA;DUPERCHY, ESTHER;AND OTHERS;SIGNING DATES FROM 20120320 TO 20120418;REEL/FRAME:032944/0807

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: NOVACTA BIOSYSTEMS LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CANTAB ANTI-INFECTIVES LIMITED;REEL/FRAME:041482/0765

Effective date: 20161114

Owner name: NOVACTA HOLDINGS PLC, MALTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVACTA BIOSYSTEMS LIMITED;REEL/FRAME:041482/0791

Effective date: 20161114

Owner name: NEW PHARMA LICENCE HOLDINGS LIMITED, MALTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVACTA HOLDINGS PLC;REEL/FRAME:041482/0828

Effective date: 20161114

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4

AS Assignment

Owner name: SPERO THERAPEUTICS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NEW PHARMA LICENCE HOLDINGS LIMITED;REEL/FRAME:051324/0497

Effective date: 20191029

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8